 The U.S.-listed shares of Novartis AG NVS, -2.53 NOVN, -0.09 fell 2.6 in afternoon trading Thursday, after the Switzerland-based drug maker said it was temporarily suspending delivery of its cancer treatments Lutathera and Pluvicto in the U.S., as part of a quality review of its production sites in Millburn, New Jersey and Ivrea, Italy. The delivery suspension follows the companys temporary, voluntary suspension of production of its radioligand therapy production sites in New Jersey and Italy, which is due to an abundance of caution while it addresses potential quality issues identified in its manufacturing process. 